Shanghai Sanwei Biotech

Shanghai Sanwei Biotech, frequently referred to as Sunway Biotech, is a pioneering Chinese biopharmaceutical company focused on the development of gene therapies and oncolytic viruses. The company achieved global prominence in 2005 by launching Oncorine (H101), the world's first oncolytic virus to receive regulatory approval for the treatment of head and neck cancer. Operating as a subsidiary of Shanghai Pharmaceuticals Holding, the company maintains a robust infrastructure for the research, development, and GMP-compliant manufacturing of viral-based biologics. Their portfolio primarily targets oncology indications, leveraging selective viral replication to treat p53-deficient tumors. The company continues to advance its pipeline of next-generation oncolytic adenoviruses and recombinant proteins.